RU2012117014A - METHOD FOR PRODUCING RECOMBINANT CAPSIDE PROTEIN OF HEPATITIS VIRUS E. RECOMBINANT VACCINE FOR PREVENTION OF VIRAL HEPATITIS E. - Google Patents

METHOD FOR PRODUCING RECOMBINANT CAPSIDE PROTEIN OF HEPATITIS VIRUS E. RECOMBINANT VACCINE FOR PREVENTION OF VIRAL HEPATITIS E. Download PDF

Info

Publication number
RU2012117014A
RU2012117014A RU2012117014/10A RU2012117014A RU2012117014A RU 2012117014 A RU2012117014 A RU 2012117014A RU 2012117014/10 A RU2012117014/10 A RU 2012117014/10A RU 2012117014 A RU2012117014 A RU 2012117014A RU 2012117014 A RU2012117014 A RU 2012117014A
Authority
RU
Russia
Prior art keywords
recombinant
protein
hepatitis
orf2
rthev
Prior art date
Application number
RU2012117014/10A
Other languages
Russian (ru)
Other versions
RU2501809C1 (en
Inventor
Михаил Александрович Крымский
Иван Андреевич Борисов
Михаил Симеонович Яковлев
Татьяна Анатольевна Семененко
Original Assignee
Закрытое акционерное общество научно-производственная компания "Комбиотех"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое акционерное общество научно-производственная компания "Комбиотех" filed Critical Закрытое акционерное общество научно-производственная компания "Комбиотех"
Priority to RU2012117014/10A priority Critical patent/RU2501809C1/en
Publication of RU2012117014A publication Critical patent/RU2012117014A/en
Application granted granted Critical
Publication of RU2501809C1 publication Critical patent/RU2501809C1/en

Links

Abstract

1. Способ получения рекомбинантного капсидного белка вируса гепатита Е генотипа 3 (rtHEV-ORF2), включающий культивирование штамма-продуцента, содержащего последовательность ДНК, кодирующую белок ORF2, в подходящих для экспрессии указанного белка условиях, выделение и очистку целевого белка, отличающийся тем, что культивируют рекомбинантный штамм дрожжей Hansenula polymorpha КБТ-11/pHEV-001, содержащий интегрированную в геном последовательность ДНК, включающую рекомбинантный ген, кодирующий полипептид rtHEV-ORF2 с аминокислотной последовательностью SEQ ID NO:1, под контролем промотора гена МОХ Hansenula polymorpha и ген LEU2 S.cerevisiae в качестве селективного маркера, а после выделения и очистки получают белок rtHEV-ORF2 в виде VLP, состоящей из мономеров с молекулярной массой мономера 56 кДа.2. Рекомбинантная вакцина для профилактики вирусного гепатита Е, содержащая эффективное количество капсидного белка вируса гепатита Е, адъювант и физиологически приемлемый разбавитель, отличающаяся тем, что в качестве антигена вируса гепатита Е вакцина содержит белок rtHEV-ORF2, полученный по способу п.1.3. Рекомбинантная вакцина по п.2, отличающаяся тем, что дополнительно содержит мертиолят.1. A method of producing a recombinant hepatitis E virus capsid protein of genotype 3 (rtHEV-ORF2), comprising cultivating a producer strain containing a DNA sequence encoding an ORF2 protein under conditions suitable for expression of said protein, isolating and purifying the target protein, characterized in that cultivate a recombinant strain of Hansenula polymorpha KBT-11 / pHEV-001 containing the DNA sequence integrated into the genome, including the recombinant gene encoding the rtHEV-ORF2 polypeptide with the amino acid sequence of SEQ ID NO: 1, under warning light gene promoter and MOX Hansenula polymorpha LEU2 S.cerevisiae gene as a selectable marker, and after isolation and purification rtHEV-ORF2 protein in a VLP, consisting of monomers with a molecular mass of 56 kDa.2 monomer. Recombinant vaccine for the prevention of viral hepatitis E, containing an effective amount of the capsid protein of the hepatitis E virus, an adjuvant and a physiologically acceptable diluent, characterized in that the vaccine contains the rtHEV-ORF2 protein obtained by the method of clause 1.3 as an antigen of the hepatitis E virus. The recombinant vaccine according to claim 2, characterized in that it further comprises thiolate.

Claims (3)

1. Способ получения рекомбинантного капсидного белка вируса гепатита Е генотипа 3 (rtHEV-ORF2), включающий культивирование штамма-продуцента, содержащего последовательность ДНК, кодирующую белок ORF2, в подходящих для экспрессии указанного белка условиях, выделение и очистку целевого белка, отличающийся тем, что культивируют рекомбинантный штамм дрожжей Hansenula polymorpha КБТ-11/pHEV-001, содержащий интегрированную в геном последовательность ДНК, включающую рекомбинантный ген, кодирующий полипептид rtHEV-ORF2 с аминокислотной последовательностью SEQ ID NO:1, под контролем промотора гена МОХ Hansenula polymorpha и ген LEU2 S.cerevisiae в качестве селективного маркера, а после выделения и очистки получают белок rtHEV-ORF2 в виде VLP, состоящей из мономеров с молекулярной массой мономера 56 кДа.1. A method of producing a recombinant hepatitis E virus capsid protein of genotype 3 (rtHEV-ORF2), comprising cultivating a producer strain containing a DNA sequence encoding an ORF2 protein under conditions suitable for expression of said protein, isolating and purifying the target protein, characterized in that cultivate a recombinant strain of Hansenula polymorpha KBT-11 / pHEV-001 containing the DNA sequence integrated into the genome, including the recombinant gene encoding the rtHEV-ORF2 polypeptide with the amino acid sequence of SEQ ID NO: 1, under warning light gene promoter and MOX Hansenula polymorpha LEU2 S.cerevisiae gene as a selectable marker, and after isolation and purification rtHEV-ORF2 protein in a VLP, consisting of monomers with a molecular mass of 56 kDa monomer. 2. Рекомбинантная вакцина для профилактики вирусного гепатита Е, содержащая эффективное количество капсидного белка вируса гепатита Е, адъювант и физиологически приемлемый разбавитель, отличающаяся тем, что в качестве антигена вируса гепатита Е вакцина содержит белок rtHEV-ORF2, полученный по способу п.1.2. Recombinant vaccine for the prevention of viral hepatitis E, containing an effective amount of a capsid protein of the hepatitis E virus, an adjuvant and a physiologically acceptable diluent, characterized in that the vaccine contains the rtHEV-ORF2 protein obtained by the method of claim 1 as an antigen of the hepatitis E virus. 3. Рекомбинантная вакцина по п.2, отличающаяся тем, что дополнительно содержит мертиолят. 3. The recombinant vaccine according to claim 2, characterized in that it further comprises thiolate.
RU2012117014/10A 2012-04-27 2012-04-27 Method for obtaining recombinant core protein of hepatitis e virus and recombinant vaccine for prophylaxis of hepatitis e virus RU2501809C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2012117014/10A RU2501809C1 (en) 2012-04-27 2012-04-27 Method for obtaining recombinant core protein of hepatitis e virus and recombinant vaccine for prophylaxis of hepatitis e virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012117014/10A RU2501809C1 (en) 2012-04-27 2012-04-27 Method for obtaining recombinant core protein of hepatitis e virus and recombinant vaccine for prophylaxis of hepatitis e virus

Publications (2)

Publication Number Publication Date
RU2012117014A true RU2012117014A (en) 2013-11-10
RU2501809C1 RU2501809C1 (en) 2013-12-20

Family

ID=49516484

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012117014/10A RU2501809C1 (en) 2012-04-27 2012-04-27 Method for obtaining recombinant core protein of hepatitis e virus and recombinant vaccine for prophylaxis of hepatitis e virus

Country Status (1)

Country Link
RU (1) RU2501809C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023231149A1 (en) * 2022-05-25 2023-12-07 Xuzhou Medical University Recombinant orthohepevirus genotype c1 orf2 protein and preparation method therefor and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745558C2 (en) * 2016-12-27 2021-03-29 Федеральное государственное бюджетное научное учреждение "Федеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН" Method of producing recombinant capsid protein of hepatitis e virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455492B1 (en) * 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US6291641B1 (en) * 1988-06-17 2001-09-18 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US6458562B1 (en) * 1998-04-09 2002-10-01 The United States Of America As Represented By The Secretary Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
RU2252748C1 (en) * 2004-02-11 2005-05-27 Солонский Александр Владимирович Method for treating viral hepatitis
CN101062941A (en) * 2007-04-27 2007-10-31 东南大学 Recombined hepatitis E hepatitis virus protein, preparation method and usage thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023231149A1 (en) * 2022-05-25 2023-12-07 Xuzhou Medical University Recombinant orthohepevirus genotype c1 orf2 protein and preparation method therefor and use thereof

Also Published As

Publication number Publication date
RU2501809C1 (en) 2013-12-20

Similar Documents

Publication Publication Date Title
JP2017522907A5 (en)
JP2022066209A (en) High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
EP2493912B1 (en) High titer recombinant influenza viruses with enhanced replication in vero cells
HRP20171213T1 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
RU2019139064A (en) Compositions and methods for the treatment of cytomegalovirus
RU2014129788A (en) HPV VACCINES
JP2012530499A5 (en)
CA2762042A1 (en) Chimeric influenza virus-like particles comprising hemagglutinin
EP3045181A1 (en) A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
RU2014116371A (en) IMPROVEMENT OF VIRUS-LIKE PARTICLES IN PLANTS
Dijkman et al. Human coronaviruses 229E and NL63: close yet still so far
TWI695842B (en) Flavivirus virus like particle
RU2013154698A (en) Obtaining a virus-like particle of the rabies virus in plants
Choi et al. Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles
RU2015152086A (en) PEPTIDES SUPPRESSING INFECTIONS OF RESPIRATORY VIRUSES, THEIR APPLICATION AND METHODS OF OBTAINING
RU2018130683A (en) ATTENUATED INFECTIOUS BRONCHITIS VIRUS
ES2554752T1 (en) Baculovirus system to express proteins that form pseudoviral particles
WO2016086576A1 (en) Vector expressing poliomyelitis virus-like granule protein and method for preparing poliomyelitis virus-like granules
Guo et al. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits
CN105821010B (en) Recombinant NDV for expressing chicken IBDV antibody and application thereof in preparation of bivalent vaccine
CN1730101A (en) O type foot-and-mouth disease virus poly-gene duplication defect type adenovirus active carrier vaccine and preparation method
CN103627718A (en) S1 and N double-antigen protein recombinant plasmid capable of expressing IBV (Infectious Bronchitis Virus) and construction method and application thereof
JP2022551805A (en) Recombinant Influenza Virus with Stabilized HA for Intraovo Replication
RU2015115898A (en) NEW MVA VIRUS AND ITS APPLICATIONS
Guo et al. The adaptation of a CTN-1 rabies virus strain to high-titered growth in chick embryo cells for vaccine development